Comparing a stem cell transplant to chemotherapy alone for new AL amyloidosis
Tests a stem cell transplant after Dara-VCD chemotherapy in adults with new AL amyloidosis.
Key facts
- Who runs it
- SWOG Cancer Research Network
- Where
- Ankeny, Ann Arbor, Atlanta, Aurora, Aventura, Baytown, Bellevue, Bethesda, Boston, Brownstown, Charlotte, Chicago, City of Saint Peters, Cleveland, Clinton Township, Clive, Collierville, Columbus, Commack, Coon Rapids, Coral Gables, Coral Springs, Creve Coeur, Cypress, Danville, Dearborn, Deerfield Beach, Derby, Des Moines, Detroit, Duarte, Durham, Edina, Effingham, Farmington Hills, Goodyear, Green Bay, Greenwich, Guilford, Harrison, Hartford, Hollywood, Houston, Huntersville, Irvine, Jackson, Kansas City, La Crosse, Lansing, Madison, Mattoon, Maywood, Memphis, Miami, Middletown, Milwaukee, Minneapolis, Montvale, Mooresville, Nassau Bay, New Haven, New York, Newberg, North Haven, North Miami, Novi, Oconto Falls, Omaha, Orange, Oregon City, Oxford, Philadelphia, Plantation, Portland, Rochester, Saint Louis Park, Saint Paul, Sheboygan, Southhaven, St Louis, Stamford, Sturgeon Bay, Sugar Land, The Woodlands, Trumbull, Tucson, Urbana, Washington D.C., Waukee, West Bloomfield, Westwood, Wilkes-Barre, Winston-Salem, and Wyandotte, United StatesSee the 117 sites
- Trial code
- Registry title
- Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 338 people, planned
- Started
- 1 Jul 2024
- Expected to end
- 29 Oct 2030
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Autologous Hematopoietic Stem Cell Transplantation
- Biopsy
- Biospecimen Collection
- Bone Marrow Aspiration
- Bone Marrow Biopsy
- Bortezomib
- Computed Tomography
- Cyclophosphamide
- Daratumumab and Hyaluronidase-fihj
- Dexamethasone
- Echocardiography
- Magnetic Resonance Imaging
- Melphalan
- Positron Emission Tomography
- Stem Cell Isolation
- Survey Administration
- Record updated
- 6 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed systemic AL amyloidosis proven by biopsy. It compares Dara-VCD chemotherapy followed by a stem cell transplant with Dara-VCD chemotherapy alone.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Systemic AL amyloidosis proven by biopsy, with measurable disease. Heart involvement must not be severe. Daily-life ability (ECOG) must be 0, 1 or 2.
- Earlier treatment
- Up to one cycle (28 days) of earlier treatment is allowed before joining. Live vaccines within 28 days before registration are not allowed.
- Biomarker or test result
- Measurable disease: a positive monoclonal serum or urine immunofixation test, or monoclonal plasma cells in bone marrow, plus a difference between involved and uninvolved free light chain (dFLC) of at least 2 mg/dL.
Main reasons for not taking part
- Multiple myeloma at the same time
- Pregnant or nursing
- Hepatitis B infection
- Uncontrolled infection
- Severe heart involvement from AL amyloidosis
The registry criteria, word for word
Show all 78 criteriaShow less
Who can take part
- STEP 1: Participants must have systemic AL amyloidosis which is biopsy proven and includes histologically-confirmed by positive Congo red stain with green birefringence on polarized light microscopy, OR characteristic appearance by electron microscopy AND confirmatory AL amyloid typing (mass spectrometry-based proteomic analysis or immunofluorescence). If there is question regarding diagnosis, consult study chairs prior to registration
- STEP 1: Participants must have measurable disease within 28 days prior to treatment if initiated prior to registration or within 28 days of registration as defined by at least one of the following:; Positive monoclonal serum immunofixation electrophoresis; Positive monoclonal urine immunofixation electrophoresis; Monoclonal plasma cells in bone marrow In addition, participants must also have a difference between the involved and uninvolved free light chain (dFLC) >= 2 mg/dL
- STEP 1: Participants may receive up to one cycle (or 28 days) of therapy prior to enrollment. If a patient receives >= 75% of 1 cycle of protocol identical Dara-VCD, this will be considered 1 cycle of protocol induction. Any patient who receives less than 75% of 1 cycle of Dara-VCD or non-protocol therapy will still be eligible but will be treated per protocol. If protocol identical therapy is initiated prior to enrollment, this treatment is not continued but rather treatment is dictated per protocol
- STEP 1: Participants may be receiving chronic corticosteroids if they are being given for disorders other than AL amyloidosis or myeloma
- STEP 1: Participant must be >= 18 years old
- STEP 1: Participant must have Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0, 1, or 2 (PS = 3 may be allowed if secondary to neuropathy)
- STEP 1: Participant must have a complete medical history and physical exam within 28 DAYS prior to registration
- STEP 1: Participants must be willing to undergo high dose chemotherapy and autologous stem cell transplantation if they are randomized to the arm receiving high dose chemotherapy and autologous stem cell transplantation
- STEP 1: Participants must be eligible to receive high dose chemotherapy with melphalan at a dose of 200 mg/m\^2 or 140 mg/m\^2 (200 mg/m\^2 is highly encouraged but not mandated). Transplant eligibility criteria are included in the general eligibility criteria listed below:; Participant must have a supine systolic blood pressure (BP) >= 90 mmHg (at registration step-1, this may by supported by midodrine; Participant must have non-severe cardiac AL (meeting all the below criteria) as defined by:; N-terminal proB-type natriuretic peptide (NT proBNP) < 5000 (if no NTproBNP, brain natriuretic peptide [BNP] must be available and < 400); Troponin T (TnT) < 0.06. If not available, one of the following two criteria must be met:; High sensitivity troponin (hsTnT) T < 75 or troponin I < 0.1ng/dL; New York Heart Association (NYHA) I or II; Cardiac ejection fraction (EF) >= 40%
- STEP 1: Hemoglobin >= 8.0 g/dL (> 5 mmol/L); red blood cell transfusion allowed up to 7 day prior to registration (within 28 days prior to registration) (NOTE: Growth factor support granulocyte colony-stimulating factor [G-CSF] is permitted per institutional guidelines)
- STEP 1: Leukocytes >= 2 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 1: Absolute neutrophil count >= 1.0 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 1: Platelets >= 50 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 1: Total bilirubin =< 1.5 times the institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =< 5 x institutional ULN (within 28 days prior to registration)
- STEP 1: Direct bilirubin =< 2.0 mg/dL (within 28 days prior to registration)
- STEP 1: Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 3x upper limit of normal (ULN) (except if secondary to hepatic involvement) (within 28 days prior to registration)
- STEP 1: Alkaline phosphatase =< 750 U/L (except if secondary to hepatic involvement) (within 28 days prior to registration)
- STEP 1: Participants must have a serum creatinine =< the institutional (I)ULN OR measured OR calculated creatinine clearance >= 30 mL/min using the following Cockcroft-Gault formula. This specimen must have been drawn and processed within 28 days prior to registration
- STEP 1: If peripheral neuropathy is present at diagnosis, participants must be grade 2 (moderate symptoms; limiting instrumental activity of daily living [ADL]) or less
- STEP 1: Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2 or better
- STEP 1: Participants must not be seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR
- STEP 1: Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to registration, if indicated
- STEP 1: Participants must not have concurrent multiple myeloma as defined by the presence of lytic bone disease, plasmacytomas, >= 60% plasma cells in the bone marrow, or hypercalcemia. Participants will not be excluded solely based on the presence of plasma cells > 10% in the bone marrow unless the plasma cell percentage exceeds >60%
- STEP 1: Participants must not have known allergies to any of the study drugs
- STEP 1: Participants must not have had a major surgery within 14 days prior to registration and be fully recovered from surgery completed within 14 days prior to registration
- STEP 1: Participants must not have a known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal
- STEP 1: Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration
- STEP 1: Participants must not have either moderate or severe persistent asthma within the past 2 years), or currently have uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study)
- STEP 1: Participants must not have uncontrolled diabetes within 28 days prior to registration
- STEP 1: Participants must not have uncontrolled blood pressure and hypertension within 14 days prior to registration. Participants must have a supine systolic BP of >= 90 mmHg
- STEP 1: Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen
- STEP 1: Participants must not have received vaccination with live attenuated vaccines within 28 days prior to Registration to Step 1
- STEP 1: Participants must not have uncontrolled infection at the discretion of the enrolling physician and to be discussed with the study chair if the participant is on active anti-infectious therapy. Any patient on active anti-microbial therapy for chronic infectious issues should be discussed with the study chair prior to enrollment
- STEP 1: Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
- STEP 1: Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwestern Oncology group (SWOG) Specimen Tracking System
- STEP 1: Participants must agree to have blood, bone marrow core biopsy and aspirate, and fat pad biopsy specimens submitted for minimal residual disease assessment and future exploratory studies
- STEP 1: Participants who can complete PRO, QOL, PRO-CTCAE questionnaires, etc. forms in English, Spanish and French must participate in the patient-reported outcomes and quality of life
- STEP 2: Participants must have met all eligibility criteria for Step-1 registration
- STEP 2: Participants must have achieved at least a partial response
- STEP 2: Participants must continue receiving at least one of study drugs (bortezomib, cyclophosphamide, or daratumumab and hyaluronidase-fihj) if another study drug (daratumumab and hyaluronidase-fihj, cyclophosphamide, or bortezomib) has been discontinued due to adverse events. Note: daratumumab and hyaluronidase-fihj cannot be permanently discontinued
- STEP 2: Participants must have completed induction therapy
- STEP 2: Participants must be registered to Step 2 within 42 days of cycle 3, day 28 of induction therapy
- STEP 2: Participants must plan to initiate their assigned consolidation therapy within 8 weeks after randomization
- STEP 2: Participants must not have experienced a MOD-PFS event
- STEP 2: Participants must have ECOG performance score (PS) of 0, 1, or 2 (PS = 3 may be allowed if secondary to neuropathy)
- STEP 2: Participant must have a complete medical history and physical exam within 28 days prior to registration
- STEP 2: Participants must be willing to undergo high dose chemotherapy and autologous stem cell transplantation if they are randomized to the arm receiving high dose chemotherapy and autologous stem cell transplantation
- STEP 2: Participants randomized to Arm 2 must be willing and able to return to a participating treatment center for their assigned treatment after transplant. Note that participants need not to have a direct relationship with the transplant center in order to register
- STEP 2: Participants must be eligible to receive high dose chemotherapy with melphalan at a dose of 200 mg/m\^2 or 140 mg/m\^2 (200 mg/m\^2 is highly encouraged but not mandated). Transplant eligibility criteria are included in the general eligibility criteria listed below:; Patient must have a supine systolic BP >= 90 mmHg (at registration step-1, this may not by supported by midodrine); Patient must have non-severe cardiac AL as defined by:; NT proBNP <5000 (if no NTproBNP, BNP must be available and < 400 pg/mL) (within 14 days prior to registration step-2); TnT < 0.06. If not available, one of the following two criteria must be met (within 14 days prior to registration step-2); hsTnT <75 or troponin I < 0.1ng/dL; NYHA I or II (within 14 days prior to registration step-2); Cardiac EF >= 40% (within 14 days prior to registration step-2)
- STEP 2: Hemoglobin > 8.0 g/dL (> 5 mmol/L); red blood cell transfusion allowed up to 7 days prior to registration (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 2: Leukocytes >= 2 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 2: Absolute neutrophil count >= 1.0 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 2: Platelets >= 50 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 2: Total bilirubin =< 1.5 times the institutional ULN unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =< 5 x institutional ULN (within 28 days prior to registration)
- STEP 2: Direct bilirubin =< 2.0 mg/dL (except if secondary to hepatic involvement) (within 28 days prior to registration)
- STEP 2: AST/ALT =< 3x upper limit of normal (ULN) (except if secondary to hepatic involvement) (within 28 days prior to registration)
- STEP 2: Alkaline phosphatase =< 750 U/L (except if secondary to hepatic involvement) (within 28 days prior to registration)
- STEP 2: Participants must have a serum creatinine =< the IULN OR calculated creatinine clearance ≥ 30 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration
- STEP 2: Participants must not have uncontrolled infection at the discretion of the enrolling physician and to be discussed with the study chair if the participant is on active anti-infectious therapy. Any patient on active anti-microbial therapy for chronic infectious issues should be discussed with the study chair prior to enrollment
- STEP 2: Participants randomized to the ASCT arm must be able to have at least 2.0 x 10\^6 CD34 cells/kg collected
- STEP 2: Participants who can complete PRO, QOL, PRO-CTCAE questionnaires, etc. forms in English, Spanish and French must participate in the patient-reported outcomes and quality of life
- STEP 3: Participants must have met all eligibility criteria for Step-1 and Step-2 registration
- STEP 3: Participants must not have had daratumumab and hyaluronidase-fihj permanently discontinued during induction or consolidation
- STEP 3: Participants must have completed induction and consolidation therapy
- STEP 3: Participants must be registered to Step 3 within the following time frames:; If randomized to Arm 1 Dara-VCD consolidation: within 28 days of completion of 3 cycles of consolidation therapy; If randomized to Arm 2 high dose chemotherapy and autologous stem cell transplantation: within 180 days following initiation of stem cell transplantation
- STEP 3: Participants must not have experienced a MOD-PFS event
- STEP 3: Participants must have ECOG performance score (PS) of 0, 1, or 2 (PS = 3 is allowed if secondary to neuropathy)
- STEP 3: Participants must have a complete medical history and physical exam within 28 DAYS prior to registration
- STEP 3: Hemoglobin > 8.0 g/dL (> 5 mmol/L); red blood cell transfusion allowed up to 7 days prior to registration (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 3: Leukocytes >= 2 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 3: Absolute neutrophil count >= 1.0 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 3: Platelets >= 50 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support [G-CSF] is permitted per institutional guidelines)
- STEP 3: Total bilirubin =< 1.5 times the institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =< 5 x institutional ULN (within 28 days prior to registration)
- STEP 3: Direct bilirubin =< 2.0 mg/dL (within 28 days prior to registration)
- STEP 3: AST/ALT =< 3x upper limit of normal (ULN) (except if secondary to hepatic involvement) (within 28 days prior to registration)
- STEP 3: Alkaline phosphatase =< 750 U/L (except if secondary to hepatic involvement) (within 28 days prior to registration)
- STEP 3: Participants must not have uncontrolled infection at the discretion of the enrolling physician and to be discussed with the study chair if the participant is on active anti-infectious therapy. Any patient on active anti-microbial therapy for chronic infectious issues should be discussed with the study chair prior to enrollment
- Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines; For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Where in United States
- UI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
- University of Michigan Rogel Cancer CenterAnn Arbor, United StatesContact: Matthew J. Pianko (principal investigator)Taking people
- Emory University Hospital MidtownAtlanta, United StatesContact: Jonathan L. Kaufman (principal investigator)Taking people
- Emory University Hospital/Winship Cancer InstituteAtlanta, United StatesContact: Jonathan L. Kaufman (principal investigator)Taking people
- Rush-Copley Medical CenterAurora, United StatesContact: Priyank P. Patel (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at AventuraAventura, United StatesContact: James E. Hoffman (principal investigator)Taking people
- Houston Methodist San Jacinto HospitalBaytown, United StatesContact: Carrie H. Yuen (principal investigator)Taking people
- Nebraska Medicine-BellevueBellevue, United StatesContact: Sarah A. Holstein (principal investigator)Taking people
- Walter Reed National Military Medical CenterBethesda, United StatesContact: Christin Destefano (principal investigator)Taking people
- Boston Medical CenterBoston, United StatesContact: Vaishali Sanchorawala (principal investigator)Taking people
- Henry Ford Cancer Institute-DownriverBrownstown, United StatesContact: Philip Kuriakose (principal investigator)Taking people
- Novant Health Presbyterian Medical CenterCharlotte, United StatesContact: Raymond Thertulien (principal investigator)Taking people
- University of IllinoisChicago, United StatesContact: Ana Maria Avila Rodriguez (principal investigator)Taking people
- Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, United StatesContact: Keith E. Stockerl-Goldstein (principal investigator)Taking people
- Case Western Reserve UniversityCleveland, United StatesContact: Timothy E. O'brien (principal investigator)Taking people
- Henry Ford Macomb Hospital-Clinton TownshipClinton Township, United StatesContact: Philip Kuriakose (principal investigator)Taking people
- UI Health Care Mission Cancer and Blood - West Des Moines ClinicClive, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
- Baptist Memorial Hospital and Cancer Center-ColliervilleCollierville, United StatesContact: Brion V. Randolph (principal investigator)Taking people
- Riverside Methodist HospitalColumbus, United StatesContact: Yvonne A. Efebera (principal investigator)Taking people
- Memorial Sloan Kettering CommackCommack, United StatesContact: Heather J. Landau (principal investigator)Taking people
- Mercy HospitalCoon Rapids, United StatesContact: David M. King (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables, United StatesContact: James E. Hoffman (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at Coral SpringsCoral Springs, United StatesContact: James E. Hoffman (principal investigator)Taking people
- Siteman Cancer Center at West County HospitalCreve Coeur, United StatesContact: Keith E. Stockerl-Goldstein (principal investigator)Taking people
- Houston Methodist Cypress HospitalCypress, United StatesContact: Carrie H. Yuen (principal investigator)Taking people
- Carle at The RiverfrontDanville, United StatesContact: Priyank P. Patel (principal investigator)Taking people
- Geisinger Medical CenterDanville, United StatesContact: Joseph P. Lynch (principal investigator)Taking people
- Henry Ford Medical Center-FairlaneDearborn, United StatesContact: Philip Kuriakose (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach, United StatesContact: James E. Hoffman (principal investigator)Taking people
- Smilow Cancer Hospital-Derby Care CenterDerby, United StatesContact: Terri L. Parker (principal investigator)Taking people
- Iowa Methodist Medical CenterDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
- UI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
- UI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
- Henry Ford HospitalDetroit, United StatesContact: Philip Kuriakose (principal investigator)Taking people
- Wayne State University/Karmanos Cancer InstituteDetroit, United StatesContact: Andrew Kin (principal investigator)Taking people
- City of Hope Comprehensive Cancer CenterDuarte, United StatesContact: Michael A. Rosenzweig (principal investigator)Taking people
- Duke University Medical CenterDurham, United StatesContact: Cristiana C. Chase (principal investigator)Taking people
- Fairview Southdale HospitalEdina, United StatesContact: David M. King (principal investigator)Taking people
- Carle Physician Group-EffinghamEffingham, United StatesContact: Priyank P. Patel (principal investigator)Taking people
- Weisberg Cancer Treatment CenterFarmington Hills, United StatesContact: Andrew Kin (principal investigator)Taking people
- CTCA at Western Regional Medical CenterGoodyear, United StatesContact: Tibor J. Kovacsovics (principal investigator)Taking people
- Saint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay, United StatesContact: Matthew L. Ryan (principal investigator)Taking people
- Saint Vincent Hospital Cancer Center Green BayGreen Bay, United StatesContact: Matthew L. Ryan (principal investigator)Taking people
- Smilow Cancer Hospital Care Center at GreenwichGreenwich, United StatesContact: Terri L. Parker (principal investigator)Taking people
- Smilow Cancer Hospital Care Center - GuilfordGuilford, United StatesContact: Terri L. Parker (principal investigator)Taking people
- Memorial Sloan Kettering WestchesterHarrison, United StatesContact: Heather J. Landau (principal investigator)Taking people
- Smilow Cancer Hospital Care Center at Saint FrancisHartford, United StatesContact: Terri L. Parker (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at HollywoodHollywood, United StatesContact: James E. Hoffman (principal investigator)Taking people
- Houston Methodist HospitalHouston, United StatesContact: Carrie H. Yuen (principal investigator)Taking people
- Houston Methodist West HospitalHouston, United StatesContact: Carrie H. Yuen (principal investigator)Taking people
- M D Anderson Cancer CenterHouston, United StatesContact: Jing Christine Ye (principal investigator)Taking people
- Methodist Willowbrook HospitalHouston, United StatesContact: Carrie H. Yuen (principal investigator)Taking people
- Novant Health Cancer Institute - HuntersvilleHuntersville, United StatesContact: Raymond Thertulien (principal investigator)Taking people
- City of Hope at Irvine LennarIrvine, United StatesContact: Michael A. Rosenzweig (principal investigator)Taking people
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, United StatesContact: Polina Bellman (principal investigator)Taking people
- Allegiance HealthJackson, United StatesContact: Philip Kuriakose (principal investigator)Taking people
- University of Kansas Cancer CenterKansas City, United StatesContact: Muhammad Umair Mushtaq (principal investigator)Taking people
- Gundersen Lutheran Medical CenterLa Crosse, United StatesContact: David E. Marinier (principal investigator)Taking people
- Karmanos Cancer Institute at McLaren Greater LansingLansing, United StatesContact: Andrew Kin (principal investigator)Taking people
- University of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison, United StatesContact: Matthew J. Brunner (principal investigator)Taking people
- University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesContact: Matthew J. Brunner (principal investigator)Taking people
- Carle Physician Group-Mattoon/CharlestonMattoon, United StatesContact: Priyank P. Patel (principal investigator)Taking people
- Loyola University Medical CenterMaywood, United StatesContact: Patrick A. Hagen (principal investigator)Taking people
- Baptist Memorial Hospital and Cancer Center-MemphisMemphis, United StatesContact: Brion V. Randolph (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at KendallMiami, United StatesContact: James E. Hoffman (principal investigator)Taking people
- University of Miami Miller School of Medicine-Sylvester Cancer CenterMiami, United StatesContact: James E. Hoffman (principal investigator)Taking people
- Memorial Sloan Kettering MonmouthMiddletown, United StatesContact: Heather J. Landau (principal investigator)Taking people
- Medical College of WisconsinMilwaukee, United StatesContact: Anita D'Souza (principal investigator)Taking people
- Abbott-Northwestern HospitalMinneapolis, United StatesContact: David M. King (principal investigator)Taking people
- Memorial Sloan Kettering BergenMontvale, United StatesContact: Heather J. Landau (principal investigator)Taking people
- Novant Health Cancer Institute - MooresvilleMooresville, United StatesContact: Raymond Thertulien (principal investigator)Taking people
- Houston Methodist Saint John HospitalNassau Bay, United StatesContact: Carrie H. Yuen (principal investigator)Taking people
- Yale UniversityNew Haven, United StatesContact: Terri L. Parker (principal investigator)Taking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Heather J. Landau (principal investigator)Taking people
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York, United StatesContact: Rajshekhar Chakraborty (principal investigator)Taking people
- Providence Newberg Medical CenterNewberg, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- Yale-New Haven Hospital North Haven Medical CenterNorth Haven, United StatesContact: Terri L. Parker (principal investigator)Taking people
- University of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami, United StatesContact: James E. Hoffman (principal investigator)Taking people
- Henry Ford Medical Center-ColumbusNovi, United StatesContact: Philip Kuriakose (principal investigator)Taking people
- Saint Vincent Hospital Cancer Center at Oconto FallsOconto Falls, United StatesContact: Matthew L. Ryan (principal investigator)Taking people
- Nebraska Medicine-Village PointeOmaha, United StatesContact: Sarah A. Holstein (principal investigator)Taking people
- University of Nebraska Medical CenterOmaha, United StatesContact: Sarah A. Holstein (principal investigator)Taking people
- UC Irvine Health- Chao Family Comprehensive Cancer CenterOrange, United StatesContact: Polina Bellman (principal investigator)Taking people
- Providence Willamette Falls Medical CenterOregon City, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- Baptist Memorial Hospital and Cancer Center-OxfordOxford, United StatesContact: Brion V. Randolph (principal investigator)Taking people
- Thomas Jefferson University HospitalPhiladelphia, United StatesContact: Adam F. Binder (principal investigator)Taking people
- University of Pennsylvania/Abramson Cancer CenterPhiladelphia, United StatesContact: Adam Waxman (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at PlantationPlantation, United StatesContact: James E. Hoffman (principal investigator)Taking people
- Providence Portland Medical CenterPortland, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- Providence Saint Vincent Medical CenterPortland, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- Oregon Health and Science UniversityPortland, United StatesNo longer taking part
- Mayo Clinic in RochesterRochester, United StatesContact: Taxiarchis Kourelis (principal investigator)Taking people
- University of RochesterRochester, United StatesContact: Frank C. Passero (principal investigator)Taking people
- Park Nicollet Clinic - Saint Louis ParkSaint Louis Park, United StatesContact: David M. King (principal investigator)Taking people
- Regions HospitalSaint Paul, United StatesContact: David M. King (principal investigator)Taking people
- United HospitalSaint Paul, United StatesContact: David M. King (principal investigator)Taking people
- Saint Vincent Hospital Cancer Center at SheboyganSheboygan, United StatesContact: Matthew L. Ryan (principal investigator)Taking people
- Sheboygan Physicians GroupSheboygan, United StatesContact: Matthew L. Ryan (principal investigator)Taking people
- Baptist Memorial Hospital and Cancer Center-DesotoSouthhaven, United StatesContact: Brion V. Randolph (principal investigator)Taking people
- Siteman Cancer Center at Christian HospitalSt Louis, United StatesContact: Keith E. Stockerl-Goldstein (principal investigator)Taking people
- Siteman Cancer Center-South CountySt Louis, United StatesContact: Keith E. Stockerl-Goldstein (principal investigator)Taking people
- Washington University School of MedicineSt Louis, United StatesContact: Keith E. Stockerl-Goldstein (principal investigator)Taking people
- Smilow Cancer Hospital Care Center at Long RidgeStamford, United StatesContact: Terri L. Parker (principal investigator)Taking people
- Saint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay, United StatesContact: Matthew L. Ryan (principal investigator)Taking people
- Houston Methodist Sugar Land HospitalSugar Land, United StatesContact: Carrie H. Yuen (principal investigator)Taking people
- Houston Methodist The Woodlands HospitalThe Woodlands, United StatesContact: Carrie H. Yuen (principal investigator)Taking people
- Smilow Cancer Hospital Care Center-TrumbullTrumbull, United StatesContact: Terri L. Parker (principal investigator)Taking people
- Banner University Medical Center - TucsonTucson, United StatesContact: Muhammad Husnain (principal investigator)Taking people
- University of Arizona Cancer Center-North CampusTucson, United StatesContact: Muhammad Husnain (principal investigator)Taking people
- Carle Cancer CenterUrbana, United StatesContact: Priyank P. Patel (principal investigator)Taking people
- MedStar Georgetown University HospitalWashington D.C., United StatesContact: Kimberley Doucette (principal investigator)Taking people
- UI Health Care Mission Cancer and Blood - Waukee ClinicWaukee, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
- Henry Ford West Bloomfield HospitalWest Bloomfield, United StatesContact: Philip Kuriakose (principal investigator)Taking people
- University of Kansas Hospital-Westwood Cancer CenterWestwood, United StatesContact: Muhammad Umair Mushtaq (principal investigator)Taking people
- Geisinger Wyoming Valley/Henry Cancer CenterWilkes-Barre, United StatesContact: Joseph P. Lynch (principal investigator)Taking people
- Novant Health Forsyth Medical CenterWinston-Salem, United StatesContact: Franklin L. Chen (principal investigator)Taking people
- Henry Ford Wyandotte HospitalWyandotte, United StatesContact: Philip Kuriakose (principal investigator)Taking people
About the trial
What the trial wants to find out
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. The stem cells are then returned to the patients to replace the blood forming cells that were destroyed by the chemotherapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs, such as cyclophosphamide and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to lower the body's immune response to help stop the growth of cancer cells. Giving a stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in patients with newly diagnosed AL amyloidosis.
The 4 groups in the trial
- Consolidation Arm I (Chemotherapy)Existing treatment, for comparison
Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes on days 1 and 15 as well as bortezomib SC over 3-5 minutes, cyclophosphamide PO or IV, and dexamethasone PO or IV on days 1, 8, 15 and 22 of each cycle. Cycles repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening and at progression. Patients undergo bone marrow aspiration and biopsy within14-28 days post consolidation treatment and at progression. Patients undergo blood and urine sample collection at screening, at the start of each cycle, and the end of treatment and during follow up or at progression.
Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, and Survey Administration
- Consolidation Arm II (Chemotherapy, ASCT)Treatment being tested
Patients undergo collection of peripheral blood stem cells. Patients receive melphalan IV for 1 cycle and then 2 days later receive the stem cell transplant IV in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening and at progression. Patients undergo bone marrow aspiration and biopsy within 60-90 days post initiation of stem cell transplant. Patients undergo blood and urine sample collection at screening, during treatment, and the end of treatment and during follow up or at progression.
Treatment: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Melphalan, Stem Cell Isolation, and Survey Administration
- Induction (Chemotherapy)Treatment being tested
Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes on days 1, 8, 15 and 22 for 2 cycles and then days 1 and 15 for cycle 3. Patients receive bortezomib SC over 3-5 minutes, cyclophosphamide PO or IV, and dexamethasone PO or IV on days 1, 8, 15 and 22 of each cycle. Cycles repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI or PET-CT and fat pad aspiration at screening. Patients undergo echocardiography at screening, the completion of induction, and at progression. Patients undergo bone marrow aspiration and biopsy at screening, post induction treatment and at progression. Patients undergo blood and urine sample collection at screening, at the start of each cycle, and the end of treatment and during follow up or at progression.
Treatment: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, and Survey Administration
- Maintenance (daratumumab and hyaluronidase-fihj)Treatment being tested
Patients receive maintenance daratumumab and hyaluronidase-fihj SC over 3-5 minutes on day 1 of each cycle. Cycles repeat every 28 days for up 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening, 12 months post consolidation treatment and at progression. Patients undergo bone marrow aspiration and biopsy 12 months post consolidation treatment and at progression. Patients undergo blood and urine sample collection at screening, during treatment, 12 months post consolidation treatment and during follow up or at progression.
Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Daratumumab and Hyaluronidase-fihj, Echocardiography, and Survey Administration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis
- Plain-language title
- Comparing a stem cell transplant to chemotherapy alone for new AL amyloidosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 May 2026